The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 133-143

  Gorski, J Christopher ^a   Jones, David R ^a   Haehner Daniels, Barbara D ^a   Hamman, Mitchell A ^a   O'Mara Jr , Edward M ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; ANTI-ANXIETY AGENTS; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INTESTINES; LIVER; MALE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; REFERENCE VALUES; SEX CHARACTERISTICS;

EID: 0031696409     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90146-1     Document Type: Article

References (49)

1. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
2. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by the members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47: 1643-57.
3. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 1984;61:27-35.
4. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
5. 14C-midazolam in humans following oral dosing. Arzneimmittelforschung 1981;31:2220-3.
6. 3. Mol Pharmacol 1997;51:741-54.
7. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe; I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
8. Wu CY, Benet LZ, Herbert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
9. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. Hepatology 1996;24:796-801.
10. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24:1121-3.
11. Hebert MF, Roberts JP, Prueksaritanant T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
12. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450111A4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
13. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
14. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara, L, Himbet JH, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
15. Sabaté I, Griñó JM, Castelao AM, Huguet J, Serón D, Blanco A. Cyclosporine-diltiazem interaction: comparison of cyclosporine levels measured with two monoclonal antibodies. Transplant Proc 1989;21:1460-1.
16. Gomez DY, Wacher VJ, Tomlanovich SJ, Herbert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
17. Gupta SK, Bakran A, Johnson RWG, Rowland M. Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 1988;25:401-2.
18. Yeates RA, Lauten H, Zimmerman T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996;34:400-5.
19. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease-inhibitors for patients with HIV disease. AIDS 1997;11:268-9.
20. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-4.
21. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
22. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
23. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and intraconazole. Clin Pharmacol Ther 1993;53:298-305.
24. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between intraconazole and triazolam. Clin Pharmacol Ther 1996;50: 326-31.
25. Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou G, et al. Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychomotor evaluation. Eur J Clin Pharmacol 1987;32:389-93.
26. Lemmens HJM, Burn AGL, Hennis PJ, Gladines MPPR, Bovill JG. Influence of age on the pharmacokinetics of alfentanil. Clin Pharmacokinet 1990;19:416-22.
27. Lew KH, Ludwig EA, Milad MA, Donavan K, Middleton E, Ferry JJ, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:402-14.
28. Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright M, Ward P. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994;55:378-84.
29. Hunt CM, Westerkam WR, Stave GM, Wilson JAP. Hepatic cytochrome P450 3A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64:189-99.
30. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath-test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. J Clin Invest 1989;83: 688-97.
31. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
32. Sitar D, Duke PC, Benthuysen JL, Sanford TJ, Smith NT. Aging and alfentanil disposition in healthy volunteers and surgical patients. Can J Anaesth 1989;36:149-54.
33. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Age-dependent cyclosporine pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986;40: 438-42.
34. Chou SY, Wilson DS, Guay DRP, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992;32:1045-9.
35. Rowland M, Towser T. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams and Wilkins; 1995.
36. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301.
37. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981;19:271-8.
38. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. J Pharmacol Exp Ther 1994;270:414-23.
39. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
40. Venkatesan K. Pharmacokinetic drug interactions with rifampin. Clin Pharmacokinet 1992;22:47-65.
41. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
42. Park GR, Manara AR, Dawling S. Extra-hepatic metabolism of midazolam. Br J Clin Pharmacol 1989;27:634-7.
43. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62.
44. Lown KS, Baily DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
45. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or intraconazole. Clin Pharmacol Ther 1997;55:481-5.
46. Jacqz E, Hall SD, Branch RA, Wilkinson GR. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with co-regulated substrate, mephobarbital. Clin Pharmacol Ther 1986;39:646-53.
47. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
48. Ohmori S, Ishii I, Kuriya SI, Taniguchi T, Rikihisa T, Hirose S, et al. Effects of clarithromycin and its metabolites on mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos 1993;21:358-63.
49. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of amino drugs. Biochem Pharmacol 1995;49:591-602.